Regulation of myocardial fibrillar collagen by angiotensin II.: A role in hypertensive heart disease?

被引:84
作者
González, A
López, B
Querejeta, R
Díez, J
机构
[1] Univ Navarra, Sch Med, Fac Med, Div Fisiopatol Cardiovasc, Pamplona 31080, Spain
[2] Univ Navarra, Univ Clin, Dept Cardiol & Cardiovasc Surg, Pamplona 31080, Spain
[3] Donostia Hosp, Div Cardiol, San Sebastian, Spain
关键词
angiotensin II; arterial hypertension; collagen; fibrosis; myocardium;
D O I
10.1006/jmcc.2002.2081
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Collagen types I and III (Col I and Col III) are the major fibrillar collagens produced by fibroblasts and myofibroblasts in the adult heart. Fibrillar collagen of the heart provides the structural scaffolding for cardiomyocytes and coronary vessels and imparts cardiac tissue with physical properties that include stiffness and resistance to deformation. In addition, fibrillar collagen may also act as a link between contractile element of adjacent cardiomyocytes and as a conduit of information that is necessary for cell function. As in other organs, collagen turnover of normal adult heart results from the equilibrium between the synthesis and degradation of Col I and Col III. A number of factors have been described that may alter the balance in favor of either the synthesis (e.g., angiotensin II-ANG II-) or the degradation. Predominance of synthesis over degradation leads to increased Col I and Col III deposition or fibrosis that accompanies cardiac diseases such as hypertensive heart disease. Fibrosis alters myocardial structure and function and adversely afects the clinical outcome of hypertensive patients. Various lines of evidence suggest that besides hypertension, systemically and/or locally produced ANG II may participate in the development of hypertensive myocardial fibrosis via activation of ANG II type 1 receptors (AT(1)R). The potential clinical relevance of this possibility is linked to the ability of antihypertensive drugs such as angiotensin converting enzyme inhibitors (ACEIs) and ATIR antagonists (ARAs) to reverse myocardial fibrosis beyond their antihypertensive efficacy. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1585 / 1593
页数:9
相关论文
共 79 条
[51]   Role of myocytes in myocardial collagen production [J].
Pathak, M ;
Sarkar, S ;
Vellaichamy, E ;
Sen, S .
HYPERTENSION, 2001, 37 (03) :833-840
[52]  
PEARLMAN ES, 1982, LAB INVEST, V46, P158
[53]   Stimulation of collagen production by transforming growth factor-β1 during differentiation of cardiac fibroblasts to myofibroblasts [J].
Petrov, VV ;
Fagard, RH ;
Lijnen, PJ .
HYPERTENSION, 2002, 39 (02) :258-263
[54]  
RATAJSKA A, 1994, J LAB CLIN MED, V124, P408
[55]  
RISTELI J, 1995, J HEPATOL, V22, P77
[56]   MOLECULAR CHARACTERIZATION OF ANGIOTENSIN-II-INDUCED HYPERTROPHY OF CARDIAC MYOCYTES AND HYPERPLASIA OF CARDIAC FIBROBLASTS - CRITICAL ROLE OF THE AT(1) RECEPTOR SUBTYPE [J].
SADOSHIMA, J ;
IZUMO, S .
CIRCULATION RESEARCH, 1993, 73 (03) :413-423
[57]  
SAPPINO AP, 1990, LAB INVEST, V63, P144
[58]   Angiotensin II, adhesion, and cardiac fibrosis [J].
Schnee, JM ;
Hsueh, WA .
CARDIOVASCULAR RESEARCH, 2000, 46 (02) :264-268
[59]   Matrix metalloproteinase degradation of extracellular matrix: biological consequences [J].
Shapiro, SD .
CURRENT OPINION IN CELL BIOLOGY, 1998, 10 (05) :602-608
[60]   Angiotensin II type1 receptor regulation and differential trophic effects on rat cardiac myofibroblasts after acute myocardial infarction [J].
Staufenberger, S ;
Jacobs, M ;
Brandstätter, K ;
Hafner, M ;
Regitz-Zagrosek, V ;
Ertl, G ;
Schorb, W .
JOURNAL OF CELLULAR PHYSIOLOGY, 2001, 187 (03) :326-335